Novel approach for treatment of cancer using immunomodulation

Abstract

The present disclosure provides a regimen for treating a subject afflicted with prostate cancer by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab. The present disclosure is based on the discovery that the combination of Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab in a specific treatment regimen is a very effective therapy to treat subjects afflicted with prostate cancer.

Description

technical field [0001] The present disclosure is in the field of immuno-oncology, and more specifically relates to a treatment comprising Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab for the treatment of prostate cancer Program. [0002] Cross References to Related Applications [0003] This application claims priority to U.S. Provisional Application No. 62 / 777,352, filed December 10, 2018, and U.S. Provisional Application No. 62 / 924,429, filed October 22, 2019, the contents of which are each for all purposes Incorporated in its entirety. Background technique [0004] Cancer is a multistep process that begins with tiny preneoplastic changes that can develop into neoplastic foci that may develop an increasing capacity to invade, grow, metastasize, and heterogeneously. Current therapies used to treat cancer involve surgery, hormone therapy, radiation therapy, chemotherapy, and immunotherapy. Immunotherapy for the treatment of cancer has evolve...

AI Technical Summary

Problems solved by technology

However, talarestat has been reported to exhibit multiple side effects at therapeutically effective doses, the most common adverse events being edema / peripheral swelling, hypotension, hypovolaemia, and dizziness

These reported adverse events and insufficient primary and secondary outcomes have limited the use of talarestat as an anticancer agent in certain cancer clinical trials

Images